Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

General Information

Offices

Cambridge, USA
222 Third Street
Suite 3120
Cambridge, MA, 02142
USA

People

President and CEO

Funding

TOTAL $44.8M
FUNDING TOTAL $44.8M
Series B, 3/2011
Shire
Merieux Developpement
$12.4M
Series B, 3/2012
Merieux Developpement
Shire
$9M
Series C, 5/2013
Merieux Developpement
Shire
$6.4M
Series D, 3/2014
Shire
Merieux Developpement
$17M

Tags

NeuroPhage Pharmaceuticals

NeuroPhage Pharmaceuticals, Inc., a biotechnology company, develops disease-modifying therapies for the treatment of neurodegenerative diseases. The company develops a protein disaggregation platform for the treatment of Alzheimer’s, Parkinson’s, Huntington’s, amyotrophic lateral and multiple sclerosis, and other neurodegenerative diseases. It offers NPT001, a drug candidate for Alzheimer’s disease to disaggregate existing plaque in preclinical animal models. The company was founded in 2006 and is headquartered in Cambridge, Massachusetts.

Recent Milestones

Videos

Screenshots

NeuroPhage Pharmaceuticals screenshot
Above: Homepage
Uploaded: 3/26/14

Sources

  1. NeuroPhage Pharmaceuticals closes $12.4M Series B round (neurophage.com) [edit]
  2. NeuroPhage extends Series B to $21.4M (neurophage.com) [edit]
  3. NeuroPhage Pharmaceuticals Raises $6.4M in Equity Financing (finsmes.com) [edit]
  4. NeuroPhage Pharmaceuticals Completes $17M Series D Financing (finsmes.com) [edit]
  5. New NeuroPhage funding to back move to Alzheimer's trial (masshightech.com) [edit]
Edit This Page
Last Edited 3/25/14

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize »

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy